GlaxoSmithKline ( GlaxoSmithKline )


GlaxoSmithKline's picture

About GlaxoSmithKline

GlaxoSmithKline started operations on 1 January 2001 following the merger of GlaxoWellcome plc and SmithKline Beecham plc, but our combined histories go back much further than that. Find out about the many products and mergers that led to the GSK we know today.

GlaxoSmithKline press release, blog etc

09/14/2018 - 07:08 ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
09/10/2018 - 18:58 GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
09/10/2018 - 16:41 GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
09/07/2018 - 18:03 GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
08/30/2018 - 14:11 European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
08/15/2018 - 16:30 ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen
08/07/2018 - 04:27 Iain Mackay appointed GSK Chief Financial Officer
07/27/2018 - 10:44 CHMP recommend Nucala (mepolizumab) for the treatment of severe eosinophilic asthma paediatric patients in Europe
07/25/2018 - 12:51 GSK reports on outcome of the FDA Advisory Committee on mepolizumab for the treatment of COPD patients on maximum inhaled therapy
07/25/2018 - 04:00 GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
07/25/2018 - 03:06 GSK delivers improvements in sales, margins and cash flow in Q2 2018
07/24/2018 - 12:09 ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
07/24/2018 - 09:34 GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK
07/20/2018 - 10:07 US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
07/12/2018 - 17:39 James Ford appointed GSK General Counsel
07/12/2018 - 17:08 Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
07/12/2018 - 15:41 US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria
06/26/2018 - 22:07 Infants may now be protected against Meningitis B with fewer doses, adding flexibility to vaccination schedules